Share-based Payment Arrangement, Expense of Xilio Therapeutics, Inc. from 30 Sep 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Xilio Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2020 to 30 Sep 2025.
  • Xilio Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,123,000, a 29% decline year-over-year.
  • Xilio Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $5,525,000, a 19% decline year-over-year.
  • Xilio Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $6,434,000, a 13% decline from 2023.
  • Xilio Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7,382,000, a 12% decline from 2022.
  • Xilio Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $8,424,000, a 70% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Xilio Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $5,525,000 $1,123,000 -$451,000 -29% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $5,976,000 $1,351,000 -$160,000 -11% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $6,136,000 $1,535,000 -$298,000 -16% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $6,434,000 $1,516,000 -$414,000 -21% 01 Oct 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
Q3 2024 $6,848,000 $1,574,000 -$287,000 -15% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $7,135,000 $1,511,000 -$289,000 -16% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $7,424,000 $1,833,000 +$42,000 +2.3% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $7,382,000 $1,930,000 +$115,000 +6.3% 01 Oct 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
Q3 2023 $7,267,000 $1,861,000 -$10,000 -0.53% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $7,277,000 $1,800,000 -$909,000 -34% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $8,186,000 $1,791,000 -$238,000 -12% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $8,424,000 $1,815,000 -$256,000 -12% 01 Oct 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
Q3 2022 $8,680,000 $1,871,000 +$780,000 +71% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $7,900,000 $2,709,000 +$1,707,000 +170% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $6,193,000 $2,029,000 +$1,235,000 +156% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $4,958,000 $2,071,000 01 Oct 2021 31 Dec 2021 10-K 02 Mar 2023 2022 FY
Q3 2021 $1,091,000 +$408,000 +60% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $1,002,000 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $794,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q3 2020 $683,000 01 Jul 2020 30 Sep 2020 10-Q 02 Dec 2021 2021 Q3

Xilio Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $6,434,000 -$948,000 -13% 01 Jan 2024 31 Dec 2024 10-K 11 Mar 2025 2024 FY
2023 $7,382,000 -$1,042,000 -12% 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
2022 $8,424,000 +$3,466,000 +70% 01 Jan 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
2021 $4,958,000 +$3,662,000 +283% 01 Jan 2021 31 Dec 2021 10-K 02 Mar 2023 2022 FY
2020 $1,296,000 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.